A major step forward in India's fight against resistant hypertension has arrived at Gleneagles Hospital, Parel, Mumbai. In partnership with Medtronic India, one of the world's leading healthcare technology companies, Gleneagles has launched a dedicated Renal Denervation (RDN) Therapy Centre, believed to be among the few structured facilities of its kind in the country. The centre targets a specific and underserved group of patients: those whose blood pressure remains dangerously uncontrolled despite taking multiple medications. With specialist-led teams, structured care pathways, and cutting-edge interventional technology now under one roof, this collaboration signals a decisive shift in how India approaches complex hypertension management.
What's Happening Right Now
Gleneagles Hospital, Parel, Mumbai, announced the launch of its Renal Denervation Therapy Centre in February 2026, in collaboration with Medtronic India. The centre is designed to address resistant hypertension, a condition where a patient's blood pressure does not come under control even after being placed on three or more blood pressure medications, including a diuretic.
The facility will offer a full care continuum: detailed patient evaluations, personalised counselling, medication optimisation, and, for eligible patients, access to renal denervation therapy itself. The multidisciplinary team includes cardiologists, nephrologists, and internal medicine specialists working in a coordinated framework rather than managing patients in silos.
The centre will be led by a team of eminent specialists including Dr. Rahul Gupta, Director and Cardiologist; Dr. Bharat Shah, Director and Nephrologist; Dr. V. M. Reddy, Senior Consultant Cardiologist; and Dr. Prashant Rajput, Senior Consultant Nephrologist. Medtronic will supply the equipment and provide ongoing medical education and training for the clinical team.
The Problem This Centre Was Built to Solve
Hypertension is one of the most prevalent chronic conditions in the world and a leading cause of premature death globally. In India, it is a key contributor to cardiovascular morbidity and mortality, fuelling rising rates of heart attack, stroke, kidney failure, and vision loss. Yet despite this enormous burden, a significant proportion of hypertensive patients remain uncontrolled. The reasons are layered: delayed diagnosis, fragmented care, inconsistent follow up, poor medication adherence, and crucially, a subgroup of patients whose blood pressure simply does not respond adequately to medications.
This last category is clinically defined as resistant hypertension. These patients face a disproportionately elevated risk of serious cardiovascular and renal complications, yet have historically had few options beyond adjusting medication doses or switching drug combinations, an approach that yields diminishing returns for many.
Dr. Rahul Gupta described the challenge plainly: many patients believe they are on treatment, yet their blood pressure remains uncontrolled. It is in precisely this gap that renal denervation therapy becomes clinically relevant.
Understanding Renal Denervation Therapy: What Is It?
Renal denervation is a catheter based, minimally invasive interventional procedure that targets overactive sympathetic nerves running along the renal (kidney) arteries. These nerves are known to play a significant role in driving elevated blood pressure. When they become chronically overactivated, they contribute to persistently high blood pressure that does not yield to medication alone.
During the procedure, a thin catheter is inserted through the femoral artery and guided to the renal arteries. Energy is then applied to disrupt the nerve signals at the vessel wall, reducing the sympathetic nervous system's contribution to blood pressure elevation. The procedure does not replace medications, it adds a layer of targeted intervention for patients in whom pharmacological therapy has proven insufficient.
The technology used at the Gleneagles centre is Medtronic's Symplicity Spyral renal denervation system, which has a growing body of evidence from international clinical trials supporting its use in carefully selected patients with resistant hypertension.
Importantly, renal denervation is not a first-line treatment. It is designed for patients who have already undergone thorough evaluation, had reversible causes of hypertension excluded, and been assessed as genuine candidates for the procedure by a specialist team.
What the Centre Offers: A Structured, End to End Care Model
One of the most significant aspects of this initiative is not just the introduction of the procedure itself, but the structured care model that surrounds it. As Dr. Bipin Chevale, CEO of Gleneagles Hospital, observed, hypertension management has long been challenged by delayed diagnosis, fragmented care, and inconsistent follow up. The new centre is designed to change that.
Patients referred to the RDN Therapy Centre can expect:
- Comprehensive evaluation: A thorough clinical workup to confirm resistant hypertension, rule out secondary causes, and assess eligibility for renal denervation therapy.
- Medication optimisation: Review and adjustment of existing antihypertensive regimens to ensure patients are on the most appropriate combination before any interventional decision is made.
- Patient education and counselling: Structured guidance on lifestyle modifications, dietary changes, medication adherence, and the long term nature of hypertension management.
- Multidisciplinary input: Cardiologists and nephrologists reviewing cases together, recognising that uncontrolled hypertension damages both the heart and the kidneys simultaneously.
- Long-term follow up: Ongoing monitoring and structured follow up post procedure to measure outcomes, adjust care, and prevent complications.
Dr. Bharat Shah, Nephrologist at Gleneagles Hospital, highlighted that long-standing uncontrolled hypertension does not only threaten the heart, it progressively damages kidney function and can lead to chronic kidney disease. The RDN centre's integrated nephrology cardiology model is designed to address this dual risk.
Why This Matters: The Bigger Picture for India and International Patients
The launch of this centre carries significance well beyond a single facility in Mumbai. India faces an enormous and growing hypertension burden, with a substantial proportion of affected individuals either unaware of their condition or unable to achieve adequate control through existing treatment pathways.
For international patients seeking advanced cardiovascular care in India, this development adds a meaningful option to the landscape. Gleneagles Hospital, Parel, is an established tertiary care facility with a track record in complex cardiac and nephrology cases. The addition of a formally structured, technology backed RDN centre, led by named specialists across cardiology and nephrology, positions it as a credible destination for patients from across South Asia, the Middle East, and Africa who require more than what standard antihypertensive therapy can offer.
Medtronic's involvement also brings global clinical infrastructure: the company's experience in evidence based technologies, alongside ongoing medical education and training for clinicians, means the programme is designed to meet international standards for quality and safety.
Key Takeaways
- Gleneagles Hospital, Parel, Mumbai, has launched a dedicated Renal Denervation Therapy Centre in partnership with Medtronic India, targeting patients with resistant or uncontrolled hypertension.
- The centre offers a full care pathway: evaluation, medication optimisation, patient education, the RDN procedure itself, and structured long term follow up.
- Renal denervation is a minimally invasive, catheter based procedure that disrupts overactive kidney nerves contributing to persistently elevated blood pressure.
- The facility is led by a multidisciplinary team of cardiologists and nephrologists and is equipped with Medtronic's Symplicity Spyral technology.
- The initiative reflects a broader recognition that fragmented, medication only approaches are insufficient for a significant subset of hypertensive patients.
- This is among the first structured, specialist led RDN centres in Mumbai, and potentially one of the few in India.
Conclusion
The launch of a dedicated Renal Denervation Therapy Centre at Gleneagles Hospital, Mumbai, marks a clinically significant development in India's approach to resistant hypertension, a condition that is common, dangerous, and historically undermanaged. By pairing advanced interventional technology from Medtronic with the structured, multidisciplinary care pathways of an established tertiary hospital, this centre fills a gap that has long existed in the treatment landscape.
For patients who have lived with dangerously high blood pressure despite years of medication, this represents a genuine new frontier. The emphasis on thorough evaluation, patient education, and long-term follow up ensures that renal denervation is deployed appropriately, not as a quick fix, but as part of a comprehensive strategy to protect the heart, brain, and kidneys from the cumulative damage of uncontrolled hypertension.
References
- Medtronic News (February 26, 2026). Gleneagles Hospital partners with Medtronic India to establish specialized advanced hypertension management centre for Renal Denervation Therapy. Retrieved from https://news.medtronic.com/Gleneagles-Hospital-partners-with-Medtronic-India-to-establish-specialized-advanced-hypertension-management-centre-for-Renal-Denervation-Therapy
- The Indian Practitioner (February 25, 2026). Gleneagles Hospital Partners with Medtronic India to Launch Renal Denervation Therapy Centre. Retrieved from https://theindianpractitioner.com/gleneagles-hospital-partners-with-medtronic-india-to-launch-renal-denervation-therapy-centre/
- IndiaMedToday (February 25, 2026). Gleneagles Hospital Mumbai Opens Dedicated Centre for Resistant Hypertension with Renal Denervation Therapy. Retrieved from https://indiamedtoday.com/gleneagles-hospital-mumbai-opens-dedicated-centre-for-resistant-hypertension-with-renal-denervation-therapy/
- The Week (February 25, 2026). Mumbai gets advanced renal denervation centre to tackle resistant hypertension. Retrieved from https://www.theweek.in/news/health/2026/02/25/mumbai-gets-advanced-renal-denervation-centre-to-tackle-resistant-hypertension.html
- BioSpectrum India (February 24, 2026). Gleneagles Hospital partners with Medtronic to launch Renal Denervation Therapy Centre in Mumbai. Retrieved from
- https://www.biospectrumindia.com/news/16/27382/gleneagles-hospital-partners-with-medtronic-to-launch-renal-denervation-therapy-centre-in-mumbai.html
Recent Blogs
FAQs
It is a dedicated facility launched by Gleneagles Hospital, Parel, Mumbai, in partnership with Medtronic India, offering structured evaluation, medication optimisation, patient counselling, and renal denervation therapy for patients with resistant hypertension.
The procedure is designed for patients whose blood pressure remains uncontrolled despite taking three or more antihypertensive medications, including a diuretic. Eligibility is determined after a thorough clinical evaluation by the specialist team.
No. Renal denervation is not a substitute for medication. It is an additional intervention for patients in whom medications alone have proven insufficient to achieve target blood pressure levels.
The centre uses Medtronic's Symplicity Spyral renal denervation system, a catheter-based technology supported by international clinical trial evidence for use in resistant hypertension.
Long-standing uncontrolled hypertension significantly raises the risk of heart attack, stroke, heart failure, chronic kidney disease, and vision loss.
Structured, specialist-led renal denervation centres remain rare in India. The Gleneagles centre is believed to be among the first formally organised facilities of its kind in Mumbai.
Yes. Gleneagles Hospital, Parel, is an established tertiary-care facility that regularly receives patients from South Asia, the Middle East, and Africa seeking advanced cardiac and nephrology care in India.
Shruti Verma has completed her M.Tech in Biotechnology with experience in medical writing and scientific content development. She specializes in translating complex biomedical and healthcare information into clear, accurate, and reader-friendly content for diverse audiences. When she is not designing content, probably she is designing graphics.
Guneet Bhatia is the Founder of HOSPIDIO and an accomplished content reviewer with extensive experience in medical content development, instructional design, and blogging. Passionate about creating impactful content, she excels in ensuring accuracy and clarity in every piece. Guneet enjoys engaging in meaningful conversations with people from diverse ethnic and cultural backgrounds, enriching her perspective. When she's not working, she cherishes quality time with her family, enjoys good music, and loves brainstorming innovative ideas with her team.